SNM, ASTRO collaborate for molecular imaging, radiation oncology

The Society of Nuclear Medicine (SNM) and the American Society for Therapeutic Radiation and Oncology (ASTRO) will cosponsor a symposium from Oct. 17-18 to examine the impact of translational advances on radiation oncology and molecular imaging.

"Collaborative forums, such as this meeting exploring intersections of molecular imaging and oncology, are critical to advancing our understanding of the underlying causes of disease," said SNM President Robert W. Atcher, PhD. "Continuing education and opportunities for colleagues to share research are essential to advancing the practice of molecular imaging—and to helping patients and their care givers gain the vital information they need in order to effectively treat disease as early as possible."

The ASTRO symposium, Translational Advances in Radiation Oncology and Cancer Imaging, will be held in Arlington, Va. and will bring medical professionals and scientists together to explore and share research on the uses of molecular imaging in the detection, diagnosis and treatment of cancer, according to the societies.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.